Recent research published in PLOS One revealed a key mechanism driving acute to chronic muscle pain and demonstrated how ...

Optimized treatment reduces the mortality risk associated with chronic heart failure, leading to improvements in both ...

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...

These drugs target some of the most pressing cancer types, including multiple myeloma, breast cancer, and bladder cancer ...

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros as of ...

New data confirm a nearly two-fold increase in Parkinson’s risk near golf courses, validating decades of naturopathic concern ...

An international study led by Paolo Fiorina from Boston Children's Hospital and in collaboration with researchers from the ...

Scientists are aiming to determine the composition and topology of physiological Ashwell-Morell receptor ligands. Their findings will help uncover the receptor's still-hidden secrets.

An international study led by Paolo Fiorina from Boston Children's Hospital and in collaboration with researchers from University of Milan highlights ...

We have a session with Microbix to discuss the Q2 results they put out this morning. You can find those on the company's website on SEDAR and the press release probably was sent to your inbox. Let's ...